Our purpose in this paper is to discuss the value of mapharsen in the treatment of syphilis by the physician in his private practice.
It is known that the majority of syphilitic patients undergoing treatment in private practice are in the late asymptomatic stage and that the diagnosis of syphilis is frequently made solely on serologic evidence.
Now that most states have, or soon will have, legislation requiring routine premarital and antepartum blood tests, many more latent asymptomatic syphilitic persons will be detected and will undergo treatment in clinics or in private practice. It has been estimated that between 50 and 90 per cent of syphilitic patients treated in private practice are asymptomatic. It is especially with regard to this large group that the determination of the diagnosis rests, in large measure, on the outcome of the serologic examination.
One of the great difficulties encountered in private practice is to
REIN CR, WISE F. MAPHARSEN IN TREATMENT OF SYPHILIS IN OFFICE PRACTICE: A STUDY BASED ON 2,342 INJECTIONS OF 113 PATIENTS. JAMA. 1939;113(22):1946–1952. doi:10.1001/jama.1939.02800470022005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: